Curative Biotechnology, Inc. (CUBT)

OTCMKTS: CUBT · Delayed Price · USD
0.0312
-0.0018 (-5.45%)
Mar 1, 2024, 3:33 PM EST - Market closed
Market Cap 16.78M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 628.92M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 444,836
Open 0.0250
Previous Close 0.0330
Day's Range 0.0250 - 0.0315
52-Week Range 0.0051 - 0.0400
Beta 227.40
Analysts n/a
Price Target n/a
Earnings Date n/a

About CUBT

Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 4
Stock Exchange OTCMKTS
Ticker Symbol CUBT
Full Company Profile

Financial Performance

Financial Statements

News

Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange

7 weeks ago - GlobeNewsWire

Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors

Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange

4 months ago - GlobeNewsWire

Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions

Appoints Paul Mich aels Co-CEO of Parent and CEO of Subsidiary Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a develo...

9 months ago - GlobeNewsWire

Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation

Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retin a Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the ...

10 months ago - GlobeNewsWire

Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study

Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for ...

1 year ago - GlobeNewsWire

Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange

Boca Raton, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for...

1 year ago - GlobeNewsWire

Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors

Appointment of Independent Director Builds Upon Biotech Expertise

1 year ago - GlobeNewsWire

Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors

Appointment of Independent Director Adds to Financial Expertise on Board BOCA RATON, Fla. , May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), ...

1 year ago - PRNewsWire

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

Appointment of Independent Director Adds to Financial Expertise on Board

1 year ago - GlobeNewsWire

Curative Biotechnology Announces Toxicology Studies Under Good Laboratory Practices (GLP) for Metformin Eye Drop Formulations for Treatment of Macular Degeneration

National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA)    BOCA RATON, Fla. , May 3, 2022 /PRNewswire/ -- Curative Biotechn...

1 year ago - PRNewsWire

Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration

National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA)

1 year ago - GlobeNewsWire

Curative Biotechnology Announces Cooperative Research and Development Agreement(CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration

BOCA RATON, Fla. , March 21, 2022 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company focused on novel treatments for rare di...

2 years ago - PRNewsWire

[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

Company's First I n -license Pipeline P roduct to E nter P re- clinical S tudies

2 years ago - GlobeNewsWire

CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION

Company's First I n -license Pipeline P roduct to E nter P re- clinical S tudies

2 years ago - GlobeNewsWire

CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO

Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients , Late-Stage Rabies Therapeutic and Age-related Macular Degeneration

2 years ago - GlobeNewsWire

Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine

BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the Company has reached agreement with Mid-Atlantic B...

2 years ago - PRNewsWire

Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board

Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Exper tise in Neurobiology

2 years ago - GlobeNewsWire

Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of Audit Committee

Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for r...

2 years ago - GlobeNewsWire

Curative Biotechnology, Inc. Files 2021 First Quarter Financials and Issues Letter to Shareholders

Boca Raton, FL, May 25, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company targeting novel treatments for r...

3 years ago - GlobeNewsWire

Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT”

Kapil Bharti, Ph.D. and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board

3 years ago - GlobeNewsWire